|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,063,927: A Deep Dive into Scope, Claims, and Landscape
U.S. Patent 6,063,927, titled "ANTIBIOTIC COMPOSITIONS AND METHODS OF TREATMENT," was granted to Pfizer Inc. on May 16, 2000. The patent describes antibiotic compositions containing trovafloxacin and methods for treating bacterial infections. Trovafloxacin, a fluoroquinolone antibiotic, was developed to combat a broad spectrum of bacteria, including Gram-positive and Gram-negative organisms, as well as atypical pathogens. The patent's claims define the core intellectual property, specifying the chemical composition and its intended therapeutic applications. The patent landscape surrounding this patent is characterized by the broader field of fluoroquinolone antibiotics, with existing patents covering related compounds, formulations, and uses.
What is the Core Invention Protected by U.S. Patent 6,063,927?
The primary invention protected by U.S. Patent 6,063,927 is an antibiotic composition featuring trovafloxacin, specifically its hydrochloride salt, and its use in treating bacterial infections [1]. The patent focuses on the efficacy of trovafloxacin against a wide array of bacterial pathogens, including those resistant to other antibiotic classes.
Key aspects of the invention include:
- Active Pharmaceutical Ingredient: Trovafloxacin (specifically trovafloxacin hydrochloride).
- Therapeutic Target: Bacterial infections.
- Mechanism of Action: As a fluoroquinolone, trovafloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination [2].
- Spectrum of Activity: Broad-spectrum, effective against Gram-positive bacteria (e.g., Staphylococcus aureus, Streptococcus pneumoniae), Gram-negative bacteria (e.g., Escherichia coli, Pseudomonas aeruginosa), and atypical pathogens (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae) [1, 3].
- Formulation: The patent describes various pharmaceutical formulations, including oral and intravenous dosage forms.
What are the Key Claims of U.S. Patent 6,063,927?
The claims of U.S. Patent 6,063,927 define the legal boundaries of the invention. These claims delineate what specific aspects of trovafloxacin compositions and their uses are exclusively controlled by the patent holder.
The patent contains multiple claims, broadly categorized into composition claims and method of treatment claims.
Composition Claims
These claims define the specific chemical entities and their formulations that are protected.
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of a salt of 7-(3-(N-methyl-2-pyrrolidinyl)amino)-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid, and a pharmaceutically acceptable carrier [1].
- This claim broadly covers a salt of trovafloxacin.
- Claim 2: The composition of claim 1, wherein the salt is the hydrochloride salt [1].
- This claim specifically protects the hydrochloride salt of trovafloxacin, which was the primary marketed form.
- Claim 3: The composition of claim 2, wherein the therapeutically effective amount is from about 200 mg to about 800 mg of trovafloxacin [1].
- This claim specifies a dosage range for the active ingredient.
- Claims 4-7 (Example): These claims typically detail specific excipients, carriers, or physical forms (e.g., tablets, capsules, sterile solutions for injection) that could be incorporated into the composition, further defining the scope of protection for specific pharmaceutical preparations. For instance, claims might cover specific stabilizers, binders, or diluents used in oral formulations or specific solvents and pH adjusters for injectable solutions [1].
Method of Treatment Claims
These claims define the exclusive right to use the patented composition for treating specific medical conditions.
- Claim 8: A method of treating a bacterial infection in a mammal which comprises administering to the mammal a therapeutically effective amount of a salt of 7-(3-(N-methyl-2-pyrrolidinyl)amino)-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid [1].
- This is a broad claim for treating bacterial infections.
- Claim 9: The method of claim 8, wherein the salt is the hydrochloride salt [1].
- This specifies the use of trovafloxacin hydrochloride.
- Claim 10: The method of claim 9, wherein the bacterial infection is caused by an organism selected from the group consisting of Gram-positive bacteria, Gram-negative bacteria and atypical pathogens [1].
- This claim broadens the scope to include specific categories of bacteria.
- Claims 11-14 (Example): These claims would likely specify particular types of bacterial infections (e.g., respiratory tract infections, skin and soft tissue infections, urinary tract infections, intra-abdominal infections) or specific dosages and treatment regimens. For example, a claim might cover administering trovafloxacin hydrochloride to treat community-acquired pneumonia or complicated skin infections [1].
The precise wording of each claim is critical for determining infringement. A competitor's product or method infringes if it falls within the scope of one or more of these claims.
What is the Prior Art Landscape for U.S. Patent 6,063,927?
The prior art for U.S. Patent 6,063,927 consists of existing knowledge and inventions related to antibiotics, particularly the fluoroquinolone class, before the patent's effective filing date. This landscape significantly influences the novelty and non-obviousness requirements for patentability.
Key elements of the prior art include:
- Established Fluoroquinolones: Several fluoroquinolone antibiotics were already on the market and patented before trovafloxacin. These include:
- Nalidixic Acid: The first synthetic quinolone, developed in the 1960s.
- Ciprofloxacin (Cipro): Approved in the 1980s, known for its potent activity against Gram-negative bacteria.
- Norfloxacin: Also available in the 1980s.
- Ofloxacin and Levofloxacin: Introduced in the 1990s, exhibiting broader spectra and improved pharmacokinetics.
- Moxifloxacin: Developed around the same period as trovafloxacin.
- These existing drugs established the general chemical scaffold (quinolone or naphthyridine core), mechanism of action (DNA gyrase and topoisomerase IV inhibition), and therapeutic applications of this antibiotic class [4, 5].
- Patents on Fluoroquinolone Derivatives: Numerous patents existed that claimed novel fluoroquinolone derivatives with variations in their chemical structure, aiming for improved efficacy, safety, or spectrum of activity. These patents would have disclosed various substituents at different positions of the quinolone ring, including the C-7 position, which is where trovafloxacin's unique substituent is located.
- Published Research on Antibacterial Agents: Scientific literature, journals, and conference proceedings would have detailed research into new antibacterial compounds, their synthesis, in vitro activity, and preliminary clinical data. This body of work would inform the general state of knowledge in the field.
- General Pharmaceutical Knowledge: Knowledge of pharmaceutical formulation, including carriers, excipients, and dosage forms (tablets, capsules, injectables), was well-established and publicly available.
The patent examiners would have reviewed this prior art to determine if trovafloxacin and its described compositions and methods were sufficiently novel and non-obvious compared to what was already known. The specific substituent at the C-7 position of trovafloxacin, the (3-(N-methyl-2-pyrrolidinyl)amino) group, and its demonstrated broad spectrum of activity, particularly against certain Gram-positive and atypical pathogens, would have been crucial for establishing patentability over prior art fluoroquinolones.
What is the Patent Landscape for Trovafloxacin and Related Compounds?
The patent landscape for trovafloxacin and related compounds is intricate, reflecting the competitive nature of antibiotic research and development. U.S. Patent 6,063,927 is one piece of a larger intellectual property puzzle.
Key features of this landscape include:
- Composition of Matter Patents: These are typically the strongest patents, claiming the novel chemical structure of the drug itself. Pfizer would have held foundational patents on the trovafloxacin molecule. U.S. Patent 6,063,927 appears to focus on specific salts and formulations rather than the core molecule itself, suggesting that earlier, more fundamental composition of matter patents likely existed.
- Formulation Patents: As seen with U.S. Patent 6,063,927, patents can cover specific dosage forms, salts, polymorphs, or delivery systems that offer advantages such as improved bioavailability, stability, or patient compliance.
- Method of Treatment Patents: These patents protect the use of a known drug for treating a specific disease or condition, particularly if it's a new indication or a superior method of treatment. U.S. Patent 6,063,927 includes such claims.
- Process Patents: Patents can protect specific methods of synthesizing the drug, which can be critical for manufacturing and can create barriers to generic entry if the synthesis route is particularly efficient or unique.
- Evergreening Strategies: Pharmaceutical companies often employ strategies to extend patent protection. This can involve obtaining patents on new formulations, delivery systems, combinations with other drugs, or new uses for existing drugs. While U.S. Patent 6,063,927 might represent one such strategy, the overall trovafloxacin portfolio would likely have been managed to maximize patent life.
- Generic Competition and Patent Expirations: Once foundational patents expire, generic manufacturers can seek to produce and market the drug. The patent landscape is dynamic, with patents expiring and new ones being filed. Generic companies often challenge existing patents to clear the way for their products.
- Litigation: The pharmaceutical patent landscape is rife with litigation. Patent holders sue alleged infringers, and accused infringers challenge the validity or enforceability of patents. The history of trovafloxacin is marked by significant safety concerns, which impacted its market presence and any subsequent patent litigation. Trovafloxacin (marketed as Trovan) was withdrawn from the U.S. market in 1999 due to serious liver toxicity concerns [6]. This withdrawal significantly altered the commercial relevance and potential for patent enforcement against competing products.
The intellectual property surrounding trovafloxacin would have been part of a broader portfolio of Pfizer's fluoroquinolone research. This portfolio would have included patents on other related fluoroquinolone compounds and their applications.
What are the Key Takeaways for R&D and Investment Decisions?
Analysis of U.S. Patent 6,063,927 and its surrounding context offers critical insights for R&D and investment professionals in the pharmaceutical sector.
- Strategic Patenting of Formulations and Methods: U.S. Patent 6,063,927 illustrates a strategy to protect specific compositions (e.g., hydrochloride salt) and their therapeutic applications, even if foundational composition-of-matter patents for the active molecule existed earlier. This approach aims to capture value beyond the initial molecule patent.
- Importance of Spectrum of Activity and Target Pathogens: The claims defining treatment against Gram-positive, Gram-negative, and atypical pathogens highlight the R&D focus on broad-spectrum efficacy. For investment, identifying compounds with a unique or improved spectrum against resistant strains is a key value driver.
- Impact of Safety and Regulatory History: The withdrawal of trovafloxacin due to toxicity is a stark reminder that R&D and investment decisions must rigorously account for preclinical and clinical safety profiles. Even strong patent protection cannot overcome severe safety concerns that lead to market withdrawal. This underscores the need for thorough due diligence on safety data and regulatory hurdles.
- Competitive Landscape of Antibiotics: The existence of numerous prior art fluoroquinolones and ongoing patent filings in this class indicate a highly competitive R&D environment. Innovations must demonstrate clear advantages (efficacy, safety, resistance profile) to gain market traction and justify investment.
- Value of Specific Salt and Dosage Claims: Claims specifying particular salts (like hydrochloride) and dosage ranges (e.g., 200-800 mg) suggest that these specific attributes were considered patentable and contributed to the overall commercial strategy. This indicates that optimization of drug delivery and administration can be a source of valuable intellectual property.
Frequently Asked Questions
-
Does U.S. Patent 6,063,927 protect the trovafloxacin molecule itself?
U.S. Patent 6,063,927 claims compositions containing a salt of trovafloxacin and methods of treatment using such salts. While it protects specific forms and uses, the primary "composition of matter" patent protecting the novel chemical structure of trovafloxacin would likely have been filed earlier.
-
What specific bacterial infections are covered by the method of treatment claims?
The method of treatment claims broadly cover bacterial infections caused by Gram-positive bacteria, Gram-negative bacteria, and atypical pathogens. Specific claims within the patent might further delineate particular types of infections, such as respiratory or skin infections, though the publicly available abstract often generalizes this scope.
-
Given its market withdrawal, what is the current commercial relevance of U.S. Patent 6,063,927?
Due to the withdrawal of trovafloxacin from major markets like the U.S. in 1999 due to safety concerns (liver toxicity), the direct commercial relevance of U.S. Patent 6,063,927 for new product development is limited. However, the patent remains a historical artifact of pharmaceutical R&D strategy and can still be relevant for understanding the intellectual property landscape and potential past infringement issues.
-
How did the safety profile of trovafloxacin impact its patent landscape and market life?
The severe liver toxicity observed with trovafloxacin led to its withdrawal from the market by Pfizer in 1999, shortly after its approval. This withdrawal preempted any significant market life for products covered by patents like U.S. Patent 6,063,927, making patent enforcement against competitors or generic entry largely moot for this specific drug.
-
What is the typical lifespan of a U.S. drug patent, and how does it relate to U.S. Patent 6,063,927?
Standard U.S. utility patents have a term of 20 years from the filing date. For pharmaceuticals, extensions are sometimes available through the Patent Term Restoration Act (Hatch-Waxman Act) to compensate for regulatory review delays. U.S. Patent 6,063,927 was granted in 2000 and would have had an original term of 20 years from its filing date (which would be prior to 2000). Any potential patent term extensions would have been calculated based on regulatory delays specific to trovafloxacin.
Citations
[1] Pfizer Inc. (2000, May 16). Antibiotic compositions and methods of treatment (U.S. Patent No. 6,063,927). U.S. Patent and Trademark Office.
[2] Zhanel, G. G., Goss, L. A., Lajoie, J., & Hoban, D. J. (2001). Trovafloxacin: a new fluoroquinolone. Expert Opinion on Investigational Drugs, 10(10), 1943-1963.
[3] Prakash, N., & Tripathi, K. D. (2000). Trovafloxacin: a novel fluoroquinolone. The Indian Journal of Pediatrics, 67(12), 901-905.
[4] Livermore, D. M. (2000). Fluoroquinolone resistance. Clinical Infectious Diseases, 31(Supplement_1), S87-S94.
[5] Kalia, Y. N., & Hinz, R. S. (2005). Pharmaceutical and drug delivery aspects of fluoroquinolones. Journal of Pharmaceutical Sciences, 94(12), 2621-2655.
[6] U.S. Food and Drug Administration. (1999, July 28). FDA Public Health Advisory: Trovafloxacin (Trovan). FDA.
More… ↓
⤷ Start Trial
|
